/
COCP
$1.10-$0.02 (-1.79%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$15.4M
14M shares
52-week range
$0.76 – $2.67
18% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change$-11.02
Cocrystal Pharma, Inc. Common Stock
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.
www.cocrystalpharma.com- Employees
- 10
- IPO / List date
- Apr 1, 2008
- HQ
- BOTHELL, WA
Held by traders on TradeandTell
No one on the platform currently holds COCP.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 123,928 | $125.2K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2022-10-11 | 1-for-12reverse |
| 2018-01-24 | 1-for-30reverse |
| 2011-03-15 | 10-for-1 |
Recent trades on TradeandTell
No one on the platform has traded COCP yet.
